The global Cancer Immunotherapy Drug Discovery Outsourcing Market size
is projected to reach USD 1.7Billion by 2025, according to a new report by
Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast
period. Increasing prevalence of cancer and rising mortality associated with
cancer, along with growing development in the field of cancer immunotherapy,
are anticipated to stimulate the growth of the market.
In order to maintain pace with increasing competition in the
cancer therapeutics industry, pharmaceutical companies spend 2.5% more than
other high tech industries in the in-house R&D. Hence, they are swiftly
shifting towards outsourcing of drug discovery in order to achieve lower
in-house R&D costs.
Additionally, favorable tax credit allows pharmaceutical
companies to appropriately plan their global projects with a reputed CRO and
therefore, receive benefits and reduce problems associated with taxation
authorities or other bodies administering such incentive programs.
Several new molecules for cancer immunotherapy and new
immunotherapeutic options, such as tumor infiltrating lymphocytes, check point
inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some
are in the pipeline and are being tested for their ability to provide better
cancer treatment
Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-drug-discovery-outsourcing-market
https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-drug-discovery-outsourcing-market
Further Key Findings From the Report Suggest:
- Monoclonal
antibodies emerged as the largest segment in 2017 because of increasing
regulatory approvals and higher efficacy
- Target
identification and validation accounted for the largest share in the
global market owing to higher costs incurred and increased investments in
new drug development
- North
America dominated the market with the largest share in 2017. Rising
incidence of cancer and increasing demand for novel technologies are
facilitating the dominance of the region during the forecast period
- Some
of the key players are Covance, Inc.; Explicyte; Aquila BioMedical;
Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation;
HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech
Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA;
Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the
cancer immunotherapy drug discovery outsourcing market.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment